Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response

Frontiers in Oncology(2022)10.3389/fonc.2022.991724Source: DataRank Database

Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.92)OA: goldTopics (39)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Steven W. Thorpe ORCID,Morgan Darrow,Janai R. Carr ORCID,Amisha Singh ORCID

Live enrichment

PubMed:36465334 PMC:PMC9713241 OpenAlex:https://openalex.org/W4309606716

National Institutes of Health

Grant: 3P30CA093373-07S2

Cancer Center Support Grant - P30

National Institutes of Health

Grant: 5K12CA138464-10

Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

FWCI

0.92

Citation Percentile

0.7%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fonc.2022.991724/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2022.991724/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fonc.2022.991724/full

journalhttps://doi.org/10.3389/fonc.2022.991724

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36465334

Fields of Study

Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and TreatmentMusculoskeletal synovial abnormalities and treatments03 medical and health sciences0302 clinical medicine

Keywords

PembrolizumabMedicineImmunotherapyOncologyChemotherapyDiseasePopulationInternal medicineCancerChondrosarcomaCase ReportDedifferentiated Chondrosarcoma (Ddcs)Immunotherapy OutcomesClinical SciencesOncology and CarcinogenesisImmunologyPrecision Medicine (rcdc)5.1 Pharmaceuticals (hrcs-rac)6163211 Oncology and carcinogenesis (for-2020)Precision Medicine32 Biomedical and Clinical Sciences (for-2020)3204 Immunology (for-2020)3202 Clinical Sciences (for-2020)RC254-2826.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical SciencesImmunotherapy (rcdc)Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancer (hrcs-hc)1112 Oncology and Carcinogenesis (for)5.1 Pharmaceuticals6.1 Pharmaceuticalsdedifferentiated chondrosarcoma

Sustainable Development Goals

SDG 0: Good health and well-being